Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
\[Dose Escalation Part\]~Inclusion Criteria:~* Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.~* ECOG Performance Status 0 or 1.~* Adequate Bone Marrow, Renal and Liver Function.~Exclusion Criteria:~* Patients with known symptomatic brain metastases requiring steroids.~* Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of study treatment.~* Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.~\[Dose Expansion Part\]~Inclusion Criteria:~* Histologically or cytologically confirmed carcinoma of the breast.~* Locally advanced breast cancer that is not amenable to curative radiation or surgery and/or metastatic disease.~* Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.~* No more than 3 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease.~* Have measurable lesion by the RECIST v.1.1.~* ECOG Performance Status 0-2.~* Adequate Bone Marrow, Renal and Liver Function.~Exclusion Criteria:~* First-line locally advanced or metastatic breast cancer with no prior neoadjuvant and adjuvant chemotherapy.~* Prior treatment with a PARP inhibitor.~* Objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease.~* HER2 positive breast cancer.~* Active inflammatory breast cancer.~* Central nervous system (CNS) metastases.~* Current or anticipated use within 7 days prior to the first dose of study treatment, or anticipated use during the study of strong P-gp inhibitors.~* Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- talazoparib (Type: EXPERIMENTAL): 0.75 mg/day or 1.0 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).